Table 2 Demographic characteristics
From: Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Characteristic | TOMORROW (IPF) n = 342a | INPULSIS-1 (IPF) n = 513 | INPULSIS-2 (IPF) n = 548 | SENSCIS (SSc-ILD) n = 576 | INBUILD (Progressive fibrosing ILD) n = 663 |
|---|---|---|---|---|---|
Age, years | 65 (8.4) | 67 (8.3) | 67 (7.8) | 54 (12.2) | 66 (9.8) |
Body weight, kg | 77 (14.7) | 82 (16.6) | 77 (16.1) | 70 (15.9) | 77 (17.4) |
Height, cm | 167 (9.0) | 169 (8.9) | 167 (9.4) | 164 (9.8) | 165 (10.0) |
FVC, % predicted | 82 (17.9) | 80 (17.1) | 79 (18.4) | 73 (16.7) | 69 (15.6) |
Race, n (%) | |||||
White | 270 (79) | 333 (65) | 275 (50) | 387 (67) | 488 (74) |
Black | 0 | 0 | 2 (< 1) | 36 (6) | 10 (2) |
Asian | 72 (21) | 106 (21) | 214 (39) | 143 (25) | 163 (25) |
American Indian/Alaska native | 0 | 1 (< 1) | 1 (< 1) | 5 (1) | 0 |
Hawaiian/Pacific Islander | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) |
Multiple | 0 | 0 | 0 | 4 (< 1) | 1 (< 1) |
Missing | 0 | 73 (14)b | 56 (10)b | 0 | 0 |
Region, n (%) | |||||
Asia | 73 (21) | 97 (19) | 225 (41) | 130 (23) | 155 (23) |
Europe | 202 (59) | 288 (56) | 187 (34) | 266 (46) | 301 (45) |
North America | 10 (3) | 70 (14) | 104 (19) | 142 (25) | 136 (21) |
Rest of the world | 57 (17) | 58 (11) | 32 (6) | 38 (7) | 71 (11) |
Underlying diagnosis (INBUILD STUDY), n (%) | |||||
HP | – | – | – | – | 173 (26) |
iNSiP | – | – | – | – | 125 (19) |
Unclassifiable IIP | – | – | – | – | 114 (17) |
Autoimmune ILDs | – | – | – | – | 170 (26) |
Other ILDs | – | – | – | – | 81 (12) |